Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

DOLOVANZ FORTE 25 MG POLVO PARA SOLUCION ORAL - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/DOLOVANZ FORTE 25 MG POLVO PARA SOLUCION ORAL

Approved

STANDARD

DOLOVANZ FORTE 25 MG POLVO PARA SOLUCION ORAL

Laboratorios Cinfa S.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: May 26, 2023
Approval ID: 085483203f401a35
Company: Laboratorios Cinfa S.A.
Type: Standard

Approval Details

Approval Id: 085483203f401a35
Drug Cima Aemps Name: DOLOVANZ FORTE 25 MG POLVO PARA SOLUCION ORAL
Register Number: 88868
Holder Company Name: Laboratorios Cinfa S.A.
Marketing Company Name: Laboratorios Cinfa S.A.
Authorization Date: 2023-05-26
Dosage Form: POLVO PARA SOLUCIÓN ORAL
Dose: 25 mg
Route Of Administration: VÍA ORAL
Prescription Type: Sin Receta
Commercialized: No
Company Name: Laboratorios Cinfa S.A.

Active Ingredients

DEXKETOPROFENO TROMETAMOL

36,90 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

May 26, 2023

Approval ID

085483203f401a35

Type

Standard

Back to CIMA-AEMPS Approvals